Galectin Therapeutic (GALT) Stock Price, Quote & News

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 620 3186

Website: galectintherapeutics.com

Address:

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

th3_fail_k1ng Dec. 5 at 5:44 PM

$GALT yup shorts attacked at open. Burned through 100k shares to drop the price 50 cents and still have 80k shares in the ammo bin. Easy hold for me.

1 · Reply

Schuuultz Dec. 5 at 5:41 PM

$GALT Today's rough seas prevent me from spotting any whales. Aside from that, all longs will do well to ride out this storm and any other storms until buyout is announced. In the words of the late Charlie Munger, "Avoid stupidity."

0 · Reply

JollyAcorn2021 Dec. 5 at 5:32 PM

$GALT A Big-Ass-Buy-Out ("BABO") is easy for me to understand and estimate impact on stock price. With a formal "partnership," I assume its a combination of cash infusion in exchange for rights to commercialize in the future for this or that particular disease. Or some combination of cash, contingent milestone payments or whatever; needless to say it more complicated. What are folks' thought on this path forward (partnership) and its impact on SP?

0 · Reply

KungFuJones Dec. 5 at 5:16 PM

$GALT Have a nice W forming on the intraday (5m-20m). Hopefully the bears are running out of steam. But we will see.

0 · Reply

oldmanrizzer Dec. 5 at 5:12 PM

$GALT Phew..Glad I didn't buy at the bell this morning! Still waiting for a reversal before I lace up the skates with this bad boy.

1 · Reply

MaryJaneSmokesalot Dec. 5 at 5:01 PM

$GALT Another 35,000 shares borrowed in the last few minutes They’ve got nothing left Imagine fighting a billionaire whose Chairmen of the Board who is conviction is so strong he refuses to dilute the stock and has invested more than $110 million of his own money Good luck shorts

1 · Reply

MzzO Dec. 5 at 4:58 PM

$GALT It's not the stock, for whatever reason Bitcoin is dragging the market down today. Because it is so heavily reliant on liquidity, and it is sto tightly coupled to tech/AI, and because we have the big 7 which are majority tech, it has a market wide effect. Don't worry liquidity is coming, a buyout most likely is coming for GALT, 6 to 60 minimum. Insane how ridiculous the valuation is right now.

3 · Reply

mcube1820 Dec. 5 at 4:58 PM

$GALT easy come, easy go.

0 · Reply

kookiemonsteryum Dec. 5 at 4:43 PM

$GALT whats everyone's prediction on closing price? What shorts would want to hold this over the weekend?! I am thinking 6.08 is what we close at. Hopefully I low balled it

2 · Reply

JollyAcorn2021 Dec. 5 at 4:33 PM

$GALT To dance the BABO...you have to have a partner!

0 · Reply

Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data

Nov 26, 2025, 2:44 AM EST - 9 days ago

Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis

Nov 14, 2025, 8:00 AM EST - 21 days ago

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

Sep 2, 2025, 8:00 AM EDT - 3 months ago

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

May 12, 2025, 8:00 AM EDT - 7 months ago

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Mar 31, 2025, 8:00 AM EDT - 8 months ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Jan 10, 2025, 8:00 AM EST - 11 months ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Dec 20, 2024, 10:29 AM EST - 1 year ago

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Dec 20, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Nov 18, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Nov 14, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

May 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 20, 2024, 8:11 PM EDT - 1 year ago

Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Dec 7, 2023, 6:00 AM EST - 2 years ago

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Nov 13, 2023, 8:45 AM EST - 2 years ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GLTO

Sep 13, 2023, 5:22 PM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Sep 7, 2023, 12:00 PM EDT - 2 years ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

May 15, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

Apr 27, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Mar 30, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 16, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Jan 24, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Jan 5, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Nov 28, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Nov 14, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Nov 1, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Oct 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming Conferences

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

Aug 15, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Jul 26, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

Jul 11, 2022, 4:16 PM EDT - 3 years ago

Galectin: Ability To Potentially Target Unmet Medical Need

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

May 23, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

th3_fail_k1ng Dec. 5 at 5:44 PM

$GALT yup shorts attacked at open. Burned through 100k shares to drop the price 50 cents and still have 80k shares in the ammo bin. Easy hold for me.

1 · Reply

Schuuultz Dec. 5 at 5:41 PM

0 · Reply

JollyAcorn2021 Dec. 5 at 5:32 PM

0 · Reply

KungFuJones Dec. 5 at 5:16 PM

$GALT Have a nice W forming on the intraday (5m-20m). Hopefully the bears are running out of steam. But we will see.

0 · Reply

oldmanrizzer Dec. 5 at 5:12 PM

$GALT Phew..Glad I didn't buy at the bell this morning! Still waiting for a reversal before I lace up the skates with this bad boy.

1 · Reply

MaryJaneSmokesalot Dec. 5 at 5:01 PM

1 · Reply

MzzO Dec. 5 at 4:58 PM

3 · Reply

mcube1820 Dec. 5 at 4:58 PM

$GALT easy come, easy go.

0 · Reply

kookiemonsteryum Dec. 5 at 4:43 PM

$GALT whats everyone's prediction on closing price? What shorts would want to hold this over the weekend?! I am thinking 6.08 is what we close at. Hopefully I low balled it

2 · Reply

JollyAcorn2021 Dec. 5 at 4:33 PM

$GALT To dance the BABO...you have to have a partner!

0 · Reply

MoneyInc Dec. 5 at 4:28 PM

$GALT test it again!

0 · Reply

derkleineprinz Dec. 5 at 4:14 PM

$GALT fck shrts ovr wknd & brn thm to hell😇🔥🔥🔥

0 · Reply

MzzO Dec. 5 at 4:03 PM

$GALT perfect support. This company board actually cares about it's retail investors, When you have that combination, and an excellent product after many years of research coming to fruition. The only sad thing is I didn't find this earlier. But I'm still early

0 · Reply

Scarlivertriumphant Dec. 5 at 4:03 PM

$GALT Besides MASH cirrhosis, there is also alcoholic cirrhosis, and metALD cirrhosis, which is a combination of metabolic disorder and alcohol use disorder. These entities have no pharmacotherapy and no treatment other than alcohol abstinence. I see every reason for the FDA to get this out to the clinic as soon as possible. The true TAM here might be much larger than we realize. Just my opinion. Good luck to all.

1 · Reply

ko00019 Dec. 5 at 4:01 PM

$GALT For the first time in 15 years (I've been in this since 2007) I actually feel like this isn't a complete speculation play. To hear Lewis and our CMO (Go Seton Hall!) so positive where this company NEVER says anything but conservative messages in the past to me is a SIGNIFICANT change in communications which I do not think they do lightly or probably without intent. I got in seeing how early tests showed people who used this with chemo stayed on chemo longer and that was my hook... never saw this all coming back then... best of luck to all and especially for those of us been here forever, and thanks to all the great inputs from so many here helping me learn

0 · Reply

History101 Dec. 5 at 3:54 PM

$GALT imagine the bullish announcements that can be made on Monday morning...can Longs even imagine being short right now?? GLTALs!!

0 · Reply

JTSawyer66 Dec. 5 at 3:48 PM

$GALT Is it me or does it seem like Friday is always a red day for the biotech sector?

0 · Reply

Rocket22fb Dec. 5 at 3:33 PM

$GALT Just my opinion on this morning's action: Big liquidity sweep to 6.66 Controlled walk-down back under 6 But no heavy selling, no real distribution, no panic volume Just recently popped up on level II, seeing the first real support all day: NSDQ: 1.2K @ 5.86 EDGX: 5K @ 5.86 OTCBB: 5K @ 5.84 GSCO (Goldman): 1.5K @ 5.74 These aren’t retail orders — this is institutional bid stacking after a stop-sweep.

1 · Reply

JBRUN Dec. 5 at 3:31 PM

$GALT yesterday volume was around 750K , today in one hour we are getting close to 200K , still believe we close green

1 · Reply

Matolemeu Dec. 5 at 3:31 PM

$GALT ignore the noise. Do your DD and ask "does the science work? Can I wait?"

0 · Reply

Gold70 Dec. 5 at 3:26 PM

$GALT shorts are naked selling don’t believe what the market is saying.

0 · Reply

2TrustHim Dec. 5 at 3:25 PM

$GALT Takeaway Fear And Let's Know New Trial Or Not We Have A Drug That works!!!

0 · Reply

Market Cap	352.02M
Revenue (ttm)	0.00
Net Income (ttm)	-47.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.73

Volume	743,400
Avg Vol	343,124
Day's Range	N/A - N/A
Shares Out	64.47M
Stochastic %K	83%
Beta	0.95
Analysts	Sell
Price Target	$6.00